COVID-19 vaccination passport, way to returning to normal life


Despite the scientific justification for issuing passports for those who have received the emerging anti-virus vaccine only, to the exclusion of others, allowing them to return to restaurants, theaters and other closed places, the administration of the US President, Joe Biden, has so far refused to impose government standards to issue such as These testimonies, according to what was reported by writer specializing in scientific affairs, Fay Flam, in a report published by the “Bloomberg” news agency.

The American writer adds that without a unified standard, it may be difficult for restaurants or other companies, to work individually in order to obtain evidence about the position of their users on obtaining the vaccine.

Flam believes that this could impede efforts to reopen some commercial interests and slow down the pace of return to normal life. The existing problem of communication in the United States is one of the main obstacles.

Experts also blamed Americans for behaving so “individually” that they do not follow the rules, even when those rules make sense.

The issuance of special passports for vaccine recipients will require a kind of precise communication that is still not available so far, in addition to a different approach to setting rules, according to what the American author said. The risks people face vary greatly in terms of age and health status, so what is reasonably safe for one person may not be the same for another.

The entire hypothesis of the passports of vaccine holders depends on the growing scientific evidence that vaccines not only provide protection from infection with the virus, but also significantly reduce the risk of mild or asymptomatic disease and transmitting the virus to others.

It is noteworthy that the risks that a person faces in a restaurant where all customers are vaccinated, diminish to a large extent. But given the unknown, which links to mutated strains of the virus, the risks are not non-existent.

For his part, says doctor and vaccine expert, Paul Offitt, who works at Children’s Hospital in Philadelphia: “Nothing is guaranteed, but I strongly believe that one greatly reduces the chances of contracting the virus when he communicates with someone who received the vaccine, rather than dealing with someone who has not get it”.

Vaccine recipients’ passports could contain all kinds of emotional and economic benefits, in addition to public health benefits. The European Union is discussing the issue of issuing passports for vaccine recipients in order to encourage summer tourism. Some airlines have also started using this to help travelers enjoy greater freedom while on their destinations.

Earlier in March, the President of the European Commission, Ursula von der Leyen, said that the executive arm of the European Union will propose a law on the development of a plan to issue a certificate for holders of the anti-corona virus vaccination, called a “green pass”.

In the end, many hope that the degree will lead to many benefits, such as travel.

In the context, the AstraZeneca laboratory defended the effectiveness of its vaccine against Covid-19 after an American organization questioned the results of clinical trials on it, while countries in the world are fighting new waves of the epidemic. With the acceleration of vaccination programs in the world, another vaccine suffered a setback Wednesday, with the decision of the Hong and Macao authorities to suspend the ongoing vaccination operations with the Pfizer / Biontech vaccine after the company that distributed this vaccine against Corona informed it of defects in the packaging of a batch of vials containing the vaccine doses.

These doubts are a blow to scientists’ hopes for a speedy vaccination, because they consider that this is the best hope for stopping the epidemic that has killed more than 2.7 million people in the world.

On Monday, the AstraZeneca laboratory defended its vaccine, which a large number of Europeans refuse to receive, stressing that it is 79% effective against the Corona virus in elderly people and does not increase the risk of blood clots, after clinical trials conducted in the United States that included 32,449 people.

The National Institute of Allergy and Infectious Diseases in the United States expressed, in a statement issued Monday evening, “its concern that AstraZeneca may have used outdated information in these trials, which led to an incomplete view of the effectiveness of the vaccine.”

The AstraZeneca laboratory pledged Tuesday to provide within 48 hours recent data to this American organization, stressing that the initial results announced were “consistent”.

The AstraZeneca vaccine was considered a mainstay in fighting the epidemic because it is cheaper and easier to store and transport compared to other vaccines.

But confidence in it declined after about 12 countries temporarily suspended its use due to a few cases of blood clots, although the World Health Organization and other bodies concluded that there was no link between this matter and the vaccine.



Please enter your comment!
Please enter your name here